NCT03722472View on ClinicalTrials.gov

Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 2, 2018

Primary Completion Date

June 15, 2020

Study Completion Date

June 15, 2020

Conditions
Pulmonary TB
Interventions
BIOLOGICAL

ID93 + GLA-SE

The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.

Trial Locations (1)

63104

Saint Louis University - Center for Vaccine Development, St Louis

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Access to Advanced Health Institute (AAHI)

OTHER

NCT03722472 - Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults | Biotech Hunter | Biotech Hunter